MP-101 will be evaluated in this study to see if it is safe and tolerable.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Cleveland Clinic
Cleveland, Ohio, United States
Regional Infectious Disease Infusion Center
Lima, Ohio, United States
Number of Participants with Adverse Events
Time frame: Up to 120 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vanderbilt Center for Human Nutrition
Nashville, Tennessee, United States